It's official... Technology has won me over.

I'm releasing my first-ever "stock system" next week.

Most readers know I'm an old-school investor. I've been in the game a long time...

When I first started investing in college, getting a copy of an annual report was tricky. You had to hope your local library carried a couple of reports from the biggest companies. And if you were searching for a smaller company's annual report, you were usually out of luck.

Shareholders could request one through the mail, and the postman would bring it to your door. But you'd have to wait a few weeks until it was delivered.

I treated a company's annual report like gold. And early in my investing days, I'd go to a broker's office to peruse single-sheet newsprint on each company from the Value Line newsletter.

In the pre-Internet days, that was the main source of information for publicly traded stocks. Each page was crammed with years of data plus the latest quarterly financials and analytics.

Today, I need reading glasses to see the material that was stuffed on these sheets...

Just by reading Value Line or an annual report, you'd have a huge leg up on other investors. You'd know how the company performed over the past year, what challenges it faced, and management's outlook for the future. That was enough to give you an edge.

Wall Street research divisions even used to send folks down to the U.S. Securities and Exchange Commission ("SEC") in Washington, D.C. to photocopy the latest filings as soon as they came in and send a messenger back to headquarters to get a head start on the competition.

That has all changed now. Today, we live in the information age, where you need much more than an annual report to keep up with other investors.

See, anyone can get thousands of pages of company documents within seconds nowadays. That means you can read all sorts of financial reports filed with the SEC, not just annual reports.

And with AI, the investing game has changed even more. There are now funds that only use AI algorithms to select and trade stocks.

After all this time, throughout all these changes in technology, I've relied on deep, fundamental research for picking stocks to buy.

I still do. And I still believe the best investment decisions are built on careful research, not speculation.

But I also believe you have to adapt to the times...

That's why, next week, I'm releasing a stock system for my subscribers.

To be clear, I'm still a fundamental investor. I care about cash flows and consistent dividend payments. That's not going to change. I would never let an algorithm pick stocks for me without diving deep into the income statements.

But my new system will tell you when you should buy a certain stock, fund, or sector you like... or when you should sell them. It's all about timing.

I'll give you an example...

On April 10, I told my Retirement Trader subscribers that they should buy the technology sector.

My system had alerted me that tech had just moved into what I call the "bullish zone." And sure enough – following that signal – the tech sector shot up 39% in just under two months.

Now, I'm not so optimistic on tech. It has moved into the "bearish zone" in my system.

Sure, sexy tech stocks are dominating the headlines today. But folks need to be careful about buying them, because my system shows that they're going to underperform over the next few months.

Unlike market headlines, which are fueled by speculation and hype, my stock system has real technology and data behind it...

In fact, it uses the same algorithm that powers the system Elon Musk uses to predict the path of 10,600 Starlink satellites at once. It's incredibly powerful.

My team and I have been working on this for a long time... And it's now ready to help my subscribers make money in just about any market environment.

I'll be covering all the details of my new system in a free webinar on July 15. I'll explain how it works and how it can spot cyclical bull and bear phases to maximize your gains.

Plus, for a limited time, you can access my system and try it for yourself – for free. That means you can type in the ticker of any of the 5,000 stocks and funds in my system... and get an instant prediction for where it could be headed next.

To learn more about what I believe is the biggest breakthrough in Stansberry Research's 27-year history, click here.

What We're Reading...

Here's to our health, wealth, and a great retirement,

Dr. David Eifrig and the Health & Wealth Bulletin Research Team
July 9, 2026

Recent Articles

View Full Archives
Subscribe to Health & Wealth Bulletin for FREE
Get the Health & Wealth Bulletin delivered straight to your inbox.
About Health & Wealth Bulletin

Here at Health & Wealth Bulletin, our manifesto is to provide a guide for living well – at a good price and on your own terms.

We've told folks the secret to life-changing income in retirement, the exit plan that every investor needs, and the key to beating the market. And our team has been on the leading edge of reporting new discoveries like immunotherapy, the dangers of BPA, the truth about cholesterol, and more.

You see, huge corporate interests and corrupt government institutions would rather people didn't know about many of these concepts... The more ignorant the people are, the better for the government and corporate interests. This keeps folks dependent... and the "nanny state" alive. That's why we spend our days uncovering the truth and sharing it with readers.

Health & Wealth Bulletin is your free guidebook to intriguing health and wealth ideas. It's all about living the best life possible.

About the Editor
Dr. David "Doc" Eifrig
Dr. David "Doc" Eifrig
Editor

Dr. David "Doc" Eifrig has one of the most remarkable resumes of anyone we know in the finance industry. After receiving his Bachelor of Arts degree from Carleton College in Minnesota, he went on to earn a Master of Business Administration degree

from Northwestern University's Kellogg School of Management. There, he graduated on the Dean's List with a double major in finance and international business.

Doc then went to work as an elite derivatives trader at the Goldman Sachs investment bank. He spent a decade on Wall Street with several major institutions, including Chase Manhattan Bank and Yamaichi Securities (then known as the "Goldman Sachs of Japan").

That's when Doc's career took an unconventional turn. Sick of the greed and hypocrisy on Wall Street, he quit his Senior Vice President position to become a doctor. He graduated from Columbia University's postbaccalaureate premedical program and eventually earned his Medical Doctor degree with clinical honors from the University of North Carolina at Chapel Hill. While in medical school, he was elected president of his class and admitted to the Order of the Golden Fleece – the highest honor awarded at the university.

Doc also completed a research fellowship in molecular genetics at Duke University and became a board-eligible eye surgeon. Along the way, he has been published in scientific journals and helped start a small biotechnology company, Mirus Bio, which was sold to Roche for $125 million in 2008.

However, frustrated by Big Medicine's many conflicts, Doc began to look for ways to talk directly with individuals. He wanted to use his background to show them how to take control of their health and wealth. In 2008, Doc joined Stansberry Research and launched his publication, Retirement Millionaire. He has gone on to launch Retirement Trader, which uses options to help people construct safe, reliable income streams. Doc's Income Intelligence seeks out income-producing investments to maximize returns. Prosperity Investor helps investors unlock massive potential gains in health care investing. Every Monday through Friday, Doc shares his views on the latest in the financial and health industries – and tips on how to improve your own life – in Health & Wealth Bulletin.

Doc has also authored five books with four-star ratings (or better) on Amazon. In his spare time, he has run three marathons and several triathlons. He owns and produces his own wine (Eifrig Cellars) in northern Sonoma County, California. Doc is also the CEO of MarketWise, Stansberry Research's parent company.

Back to Top